A study of MEN1309 (OBT076) for the treatment of Non-Hodgkin Lymphoma (NHL), triple negative metastatic breast cancer and other solid cancers.

Trial Profile

A study of MEN1309 (OBT076) for the treatment of Non-Hodgkin Lymphoma (NHL), triple negative metastatic breast cancer and other solid cancers.

Planning
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs MEN 1309 (Primary)
  • Indications Breast cancer; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 31 Jan 2017 New trial record
    • 26 Jan 2017 According to a Oxford BioTherapeutics media release, the company plans to initiate this study in mid-2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top